Who is sponsoring NCT03953261?

NCT03953261 is sponsored by Loma Linda University.

What drugs are being tested in NCT03953261?

Interventions in NCT03953261: Curcumin supplement.

What condition does NCT03953261 study?

NCT03953261 studies Systemic Lupus Erythematosus.

Is NCT03953261 still recruiting?

NCT03953261 is currently terminated. Last updated 5 August 2022.

Last reviewed 2022-08-05 · How we verify

NCT03953261

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Curcumin on Systemic Lupus Erythematosus

Terminated Phase 2 Last updated 5 August 2022

What this trial tests

Phase 2 trial testing Curcumin supplement in Systemic Lupus Erythematosus in 23 participants. Terminated before completion.

Timeline

1 September 2019

Primary endpoint
13 April 2022

13 April 2022

Quick facts

Lead sponsor	Loma Linda University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	23
Start date	1 September 2019
Primary completion	13 April 2022
Estimated completion	13 April 2022
Sites	1 location across United States

Drugs / interventions tested

Curcumin supplement — full drug profile →

Conditions studied

Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →

Sponsor

Loma Linda University

Who can join

18 and older, any sex, with Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subjects with rheumatoid arthritis as well as osteoarthritis have also found benefit for their disease activity.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New developments in systemic lupus erythematosus.
Tsang-A-Sjoe MWP, Bultink IEM. · · 2021 · cited 23× · PMID 34951924 · DOI 10.1093/rheumatology/keab498
Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases.
Zhai Z, Huang Y, Zhang Y, Zhao L, et al · · 2022 · cited 11× · PMID 36009283 · DOI 10.3390/antiox11081564

Verify or expand the search:

Other recruiting trials for Systemic Lupus Erythematosus

Currently open trials in the same condition.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) · Phase 1 · recruiting

Other Loma Linda University trials

Trials by the same sponsor.

NCT07213843 — Combined Circulatory and Dietary Interventions for Neuropathy · NA · not yet recruiting
NCT07130812 — Blood Flow Restriction Training as a Targeted Intervention for Rowers With Back Pain. · NA · recruiting
NCT06673342 — Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake · NA · completed
NCT06445842 — Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women · NA · recruiting
NCT07396831 — Necessity of Post-operative Eye Drops · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03953261 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Loma Linda University
Last refreshed: 5 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03953261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing